Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Further Reading from MarketBeat.com Why CorMedix Could be the Biopharma Name to Watch Early in 2026Submitted by Nathan Reiff. Originally Published: 12/23/2025. 
Summary - CorMedix is best known for its catheter lock solutions, products designed to reduce the risk of infection for dialysis patients.
- DefenCath is one of the company's leading products, having recently achieved promising results in both reducing catheter-related infections and related hospitalizations.
- The company's other leading candidate, REZZAYO, should see Phase III trial data in early 2026.
An often-overlooked risk for patients receiving dialysis for kidney failure or related conditions is infection. Unfortunately, infections among dialysis patients are both common and serious, creating a significant complication and unmet medical need. CorMedix Inc. (NASDAQ: CRMD), a clinical-stage biopharmaceutical company, is developing catheter lock products intended to prevent certain dialysis-related bloodstream infections and may be well positioned to address this gap. The company's catheter lock solution (CLS), DefenCath, provides antimicrobial protection for central venous catheter users. Interim results the company announced in mid-December 2025 are promising and support a broadly bullish outlook. Investors seeking a commercial execution story with a clear clinical proof point should watch CorMedix into early 2026. DefenCath Real-World Data Show a 72% Drop in Bloodstream Infections A new trading briefing is drawing attention to a little-discussed policy-driven market theme some traders believe could create short-term opportunities.
In a recent video, a veteran technical analyst walks through how this setup works, why it's showing unusual momentum, and how active traders are approaching it using defined, time-bound strategies rather than long-term buy-and-hold positions. Watch the trading briefing here DefenCath's real-world evidence study, ongoing since mid-2024, has shown a 72% reduction in catheter‑related bloodstream infections and a 70% reduction in related hospitalizations among patients. The treatment appears to meaningfully lower infection risk and, as a result, can reduce the substantial costs associated with treating bloodstream infections. In its latest earnings release, CorMedix said DefenCath adoption is outpacing expectations, with utilization well above the company's 6,000-patient target. CorMedix is preparing for add-on periods beginning in summer 2026 and will spend the coming months finalizing supply pricing under existing contracts and increasing utilization among Medicare Advantage patients. Melinta Adds Revenue Streams and Expands the Anti-Infective Footprint CorMedix is also exploring growth opportunities beyond hemodialysis. In August, it completed the acquisition of Melinta Therapeutics. Melinta's portfolio generated about $13 million in sales in September alone, suggesting meaningful synergy potential. Its products, which include treatments for various fungal and bacterial infections, broaden and diversify CorMedix's commercial base. Financial Leverage Is Showing Up in 2025 Guidance DefenCath is already translating into headline financial momentum. CorMedix reported $104.3 million in net revenue for the third quarter of 2025 and raised its full-year 2025 pro forma net revenue guidance to $390 million–$410 million, up from prior guidance of $375 million. The company benefited from a nearly $60 million tax benefit in the latest quarter and expects additional cash benefits from tax savings and carryforwards against future taxable income. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of nearly $72 million represented a large improvement versus a $2 million loss in the year-ago quarter. Management now expects full-year adjusted EBITDA of $220 million to $240 million. REZZAYO Phase III Data in 2Q 2026 Could Be a High-Impact Catalyst Candidemia treatment REZZAYO is one of CorMedix's primary pipeline products and is in a Phase III trial that completed enrollment in September 2025. Outside of growth from the Melinta acquisition, REZZAYO could be the company's top near-term growth driver. Trial data are expected in the second quarter of 2026 and, if positive, could provide an additional catalyst for the stock. A favorable readout could shift the narrative from "commercial ramp plus real-world data" to "commercial ramp plus pipeline expansion," giving investors another reason to focus on CorMedix beyond quarterly utilization updates. Risks to Watch: Pricing, Concentration, Reimbursement, and Execution Analysts are generally optimistic about CorMedix's prospects. The company has near-unanimous Buy ratings on Wall Street, and analysts see more than 48% upside potential even after CRMD shares have already climbed roughly 51% this year. That said, investors should weigh several risks before opening a new position. CorMedix faces pricing pressure, customer concentration, and reimbursement uncertainties around DefenCath. The company's pipeline is not as deep as some peers in the biopharma sector, which makes CorMedix relatively reliant on a small set of products. As with all clinical-stage biopharma names, CorMedix carries both meaningful risk and substantial upside. Early DefenCath success is encouraging, but the durability of adoption—and whether 2026 catalysts deliver—will determine whether CorMedix can sustain its current trajectory into 2026.
| 
Post a Comment
Post a Comment